Literature DB >> 22592631

Elevation of alanine transaminase and markers of liver fibrosis after a mixed meal challenge in individuals with type 2 diabetes.

E Y H Khoo1, M C Stevenson, E Leverton, R Cross, J W Eriksson, S M Poucher, I Spendlove, P G Morris, I A Macdonald, P Mansell, G P Aithal.   

Abstract

BACKGROUND: Hyperalimentation for 4 weeks is associated with raised liver enzymes and liver fat content (LFC), which are two common features found in individuals with diabetes. AIM: We evaluated the effect of two mixed meal challenges on LFC, liver enzymes and serum bio-markers of liver injury and fibrosis in 16 healthy volunteers (HV) and subjects with type 2 diabetes (T2DM).
METHODS: Subjects (HV: 9 male, 7 female, aged 57.9 ± 1.7 years, body mass index (BMI) 27.1 kg/m(2); and T2DM: 11 male, 5 female, aged 62.1 ± 1.3 years, BMI 28.0 ± 0.4 kg/m(2)) consumed two meals at 1 h (884 kcal) and at 6 h (1,096 kcal). LFC determined by (1)H magnetic resonance spectroscopy, serum levels of liver enzymes, hyaluronic acid (HA), procollagen III N-terminal peptide (P3NP) and tissue inhibitor metalloproteinase-1 (TIMP-1) were estimated at time 0 (fasting) and 9 h (postprandial).
RESULTS: Fasting LFC was higher in the T2DM group 7.6 % (4.9, 15.4) [median (inter-quartile range)] than in the HV group 2.3 % (0.8, 5.1) (p < 0.05) while levels of HA, P3NP and TIMP-1 were similar. Following the meal challenge there was no significant change in LFC. Subjects with T2DM had higher post-prandial rise in alanine transaminase (ALT) (p = 0.014), serum HA (p = 0.007) and P3NP (p = 0.015) compared with HV. Fasting LFC correlated with a greater post-prandial increase in P3NP levels in all subjects (Pearson correlation r = 0.53, p = 0.001).
CONCLUSIONS: In subjects with T2DM, a mixed meal challenge is associated with a significant elevation in the serum levels of ALT, HA and P3NP without significant changes in LFC. These markers should be performed in the fasted state.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22592631     DOI: 10.1007/s10620-012-2219-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

1.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Authors:  Kerry L Donnelly; Coleman I Smith; Sarah J Schwarzenberg; Jose Jessurun; Mark D Boldt; Elizabeth J Parks
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

2.  Connective tissue metabolites in serum as markers of disease activity in patients with rheumatoid arthritis.

Authors:  K Hørslev-Petersen; K D Bentsen; P Halberg; P Junker; K I Kivirikko; K Majamaa; L Risteli; J Risteli; I Lorenzen
Journal:  Clin Exp Rheumatol       Date:  1988 Apr-Jun       Impact factor: 4.473

3.  Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content.

Authors:  Mirja Tiikkainen; Robert Bergholm; Satu Vehkavaara; Aila Rissanen; Anna-Maija Häkkinen; Marjo Tamminen; Kari Teramo; Hannele Yki-Järvinen
Journal:  Diabetes       Date:  2003-03       Impact factor: 9.461

4.  NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study.

Authors:  Leon A Adams; Oliver R Waters; Matthew W Knuiman; Robert R Elliott; John K Olynyk
Journal:  Am J Gastroenterol       Date:  2009-03-17       Impact factor: 10.864

5.  A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

Authors:  Austin Nelson; Dawn M Torres; Ana E Morgan; Christopher Fincke; Stephen A Harrison
Journal:  J Clin Gastroenterol       Date:  2009 Nov-Dec       Impact factor: 3.062

6.  Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity.

Authors:  Elisa Fabbrini; Faidon Magkos; B Selma Mohammed; Terri Pietka; Nada A Abumrad; Bruce W Patterson; Adewole Okunade; Samuel Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-24       Impact factor: 11.205

7.  Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.

Authors:  Indra Neil Guha; Julie Parkes; Paul Roderick; Dipanker Chattopadhyay; Richard Cross; Scott Harris; Philip Kaye; Alastair D Burt; Steve D Ryder; Guruprasad P Aithal; Christopher P Day; William M Rosenberg
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

8.  Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction.

Authors:  Erik Kirk; Dominic N Reeds; Brian N Finck; S Mitra Mayurranjan; Mitra S Mayurranjan; Bruce W Patterson; Samuel Klein
Journal:  Gastroenterology       Date:  2009-01-25       Impact factor: 22.682

9.  Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study.

Authors:  Hyeon Chang Kim; Chung Mo Nam; Sun Ha Jee; Kwang Hyub Han; Dae Kyu Oh; Il Suh
Journal:  BMJ       Date:  2004-03-17

10.  The prevalence and etiology of elevated aminotransferase levels in the United States.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

View more
  2 in total

1.  PRC1 promotes GLI1-dependent osteopontin expression in association with the Wnt/β-catenin signaling pathway and aggravates liver fibrosis.

Authors:  Shenzong Rao; Jie Xiang; Jingsong Huang; Shangang Zhang; Min Zhang; Haoran Sun; Jian Li
Journal:  Cell Biosci       Date:  2019-12-16       Impact factor: 7.133

2.  Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD.

Authors:  James H Lewis; Michel Jadoul; Geoffrey A Block; Melanie P Chin; Deborah A Ferguson; Angie Goldsberry; Colin J Meyer; Megan O'Grady; Pablo E Pergola; Scott A Reisman; W Christian Wigley; Glenn M Chertow
Journal:  Clin Transl Sci       Date:  2020-09-03       Impact factor: 4.689

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.